feedback

Course Director

Justin F. Gainor, MD
Justin F. Gainor, MD

Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Faculty

Edward B. Garon
Edward B. Garon, MD, MS

UCLA's Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Kurt Schalper
Kurt Schalper, MD, PhD

Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CNE
Credit Amount:1.5 Credits
Release Date:2019-Apr-26
Expiration Date:2020-Apr-25
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer.

Upon completion of this activity, participants will be able to:
  • Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies
  • Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera)
  • Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, other cancer care and laboratory professionals, and researchers interested in cancer immunotherapies, biomarkers, and precision immuno-oncology.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CC/CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CC/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: April 26, 2019 - April 25, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CC/CNE activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CC/CNE activity during the past 12 months.

Course Director and Moderator

Justin F. Gainor, MD
Director of Targeted Immunotherapy
Henri and Belinda Center for Targeted Therapies
Massachusetts General Hospital
Assistant Professor
Harvard Medical School
Boston, Massachusetts

Justin F. Gainor, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agios Pharmaceuticals Inc.; Amgen Inc.; Ariad/Takeda; Array BioPharma; Bristol-Myers Squibb; Clovis Oncology; Genentech, Inc./F. Hoffmann-La Roche; Jounce Therapeutics, Inc.; Loxo Oncology; Merck & Co., Inc.; Oncorus; Pfizer; and Regeneron Pharmaceuticals, Inc.
Grant/Research Support from Adaptimmune; Alexo (ALX Oncology); Ariad/Takeda; Blueprint Medicines; Bristol-Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche; Jounce Therapeutics, Inc.; Merck & Co., Inc.; Moderna, Inc.; Novartis Pharmaceuticals Corporation; and TESARO Inc.

Justin F. Gainor, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies, immunotherapy-based combinations, and/or biomarkers.

Faculty

Edward B. Garon, MD, MS
Director, Thoracic Oncology Program
Health Sciences Associate Professor
Department of Medicine
Division of Hematology-Oncology
UCLA's Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Edward B. Garon, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Dracen and EMD Serono, Inc.
Grant/Research Support from AstraZeneca; Bristol-Myers Squibb; Dynavax Technologies Corporation; Eli Lilly and Company; Genentech, Inc.; Iovance Biotherapeutics, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; and Novartis Pharmaceuticals Corporation.

Edward B. Garon, MD, MS, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies, immunotherapy-based combinations, and/or biomarkers.

Kurt Schalper, MD, PhD
Assistant Professor of Pathology and Medicine
Yale School of Medicine
Director, Translational Immuno-Oncology Laboratory
Yale Cancer Center
New Haven, Connecticut

Kurt Schalper, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie; Astra Zeneca; Celgene Corporation; Moderna Therapeutics; and Shattuck Labs.
Grant/Research Support from Bristol-Myers Squibb; Merck & Co., Inc.; Moderna Therapeutics; Navigate BioPharma; Pierre Fabre; Surface Oncology; TESARO, Inc.; and Vasculox, Inc./Tioma Therapeutics.

Kurt Schalper, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies, immunotherapy-based combinations, and/or biomarkers.

Content Reviewers

Howard J. Lee, MD, has no financial interests/relationships or affiliations in relation to this activity.

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Janice Trainor-Tellier, MSN, RN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Kristin Tomlinson, PhD
PVI, PeerView Institute for Medical Education

Kristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CC/CNE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ACPE Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Continuing Certification Statement

The activity titled “New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine and Expand the Use of Cancer Immunotherapies and Combinations” has been registered to offer 1.5 Lifelong Learning (Part II) credits in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Participation information will be shared with ABPath through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.5 contact hour(s).

Providership


This CME/MOC/CC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported through educational grants from Bristol-Myers Squibb, Foundation Medicine, Inc., Incyte Corporation, and Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CC/CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.